# QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer

Source: https://onco.cc/trials/nct07636226/  
OnCo record `nct07636226` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of iparomlimab and tuvonralimab and anlotinib in lung cancer, run by Sun Yat-sen University, not yet recruiting.

## Summary

QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer is a phase 2/3, randomised interventional study registered as NCT07636226 by Sun Yat-sen University, with a registry enrolment figure of 120 participants, started 2026-07-30 and due to reach its primary completion in 2028-12-30. Interventions recorded: QL1706; Anlotinib. Conditions listed: Small Cell Lung Cancer. Primary outcome: OS. Lung eligibility wording from the registry: "Small cell lung cancer or lung squamous cell carcinoma confirmed by tissue or pathological examination". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07636226
- Phase: 2/3
- Setting: A Multicenter, Open-label, Randomized Controlled Phase II/III Study Evaluating the Efficacy and Safety of QL1706 in Combination With Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer
- Sponsor: Sun Yat-sen University
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT07636226: https://clinicaltrials.gov/study/NCT07636226

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Anlotinib](https://onco.cc/drugs/anlotinib/), [Iparomlimab and tuvonralimab](https://onco.cc/drugs/iparomlimab-tuvonralimab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07636226.json